Related Experiment Video

Updated: Aug 24, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists

Sheng Wang1, Baohua Zhang, Douglas V Faller

  • 1Boston University School of Medicine, Cancer Research Center, Boston, MA 02118, USA. sw184@bu.edu

The EMBO Journal
|May 14, 2004
PubMed

Insights

Estrogen antagonists halt breast cancer cell growth by engaging prohibitin and chromatin modifiers Brg1/Brm via a JNK1 pathway. This discovery identifies new therapeutic targets for overcoming resistance in breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Signaling

Background:

  • Estrogen antagonists are crucial in breast cancer therapy but face limitations due to acquired cellular resistance.
  • The precise molecular mechanisms underlying estrogen antagonist-induced breast cancer cell proliferation inhibition are not fully understood.
  • Emerging research indicates the E2F pathway plays a role in tamoxifen-mediated growth arrest.

Purpose of the Study:

  • To elucidate the molecular mechanisms of estrogen antagonist-mediated growth suppression in breast cancer cells.
  • To identify key cellular components involved in estrogen antagonist action.
  • To explore differences in signaling pathways activated by estrogen, estrogen deprivation, and estrogen antagonists.

Main Methods:

  • Investigated the role of prohibitin and chromatin modifiers (Brg1/Brm) in estrogen receptor-mediated growth suppression.
  • Utilized JNK1 pathway activation to study the recruitment of prohibitin/Brg1/Brm to E2F.
  • Compared signaling pathways triggered by estrogen, estrogen deprivation, and estrogen antagonists.

Main Results:

  • Demonstrated that prohibitin and Brg1/Brm are essential for estrogen antagonist-induced growth suppression.
  • Showed that recruitment of prohibitin/Brg1/Brm to E2F is mediated by the JNK1 pathway.
  • Identified distinct mechanistic differences between estrogen signaling, estrogen deprivation, and estrogen antagonist signaling.

Conclusions:

  • The prohibitin/Brg1/Brm complex acts as a critical cellular target for estrogen antagonists.
  • These findings suggest prohibitin/Brg1/Brm as potential therapeutic targets to overcome resistance in breast cancer treatment.
  • Understanding these pathways offers new avenues for developing more effective breast cancer therapies.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...